

HPV vaccination: What do I need to know?

GARDASIL® 9
Human Papillomavirus
9-valent Vaccine, Recombinant




What is Human Papillomavirus (HPV)?




Human papillomavirus (HPV) is a double-stranded DNA virus that infects the skin and mucosae of the upper respiratory and anogenital tracts¹



HPV viruses are classified as either 'high-risk' or 'low-risk' types, depending on their association with the development of HPV-related cancers¹



There are around **100 types of HPV**, of which ~40 infect the genital tract¹



HPV is associated with certain cancers, including of the cervix, vulva, vagina, and anus^{1,2}

For most people, HPV clears on its own.

But for those who don't clear the virus, it can cause certain cancers and diseases.

Who can be affected by HPV?




HPV poses risks to both **men and women**¹



4 out of 5 sexually active individuals may become infected with at least one type of HPV at some point in their lives³

What are the risks of HPV?




A minority of persistent infections with high-risk HPV types will eventually lead to certain HPV-related cancers, however, these infections **may lay dormant for 20 years or more**²




80-90% of all anal cancers are associated with HPV infection, with HPV16 and HPV18 accounting for the majority of anal cancers¹




Low-risk HPV types can lead to genital warts, which is the most commonly diagnosed viral sexually transmitted infection in the UK²



99.7% of cervical cancer cases are caused by persistent infection with high-risk HPV types⁴



79% HPV16 and HPV18 account for almost **80% of all invasive cervical cancers** in the UK⁵



of all **genital warts** are caused by **HPV6 and HPV11**¹



Want to learn more?

Click on the link below to access more resources on HPV including:

- What is the impact of HPV vaccination to date?
- How can you improve HPV vaccination uptake?
- What strategies can GP practices implement to increase HPV vaccination rates?

Clicking the link above will take you to a promotional MSD webpage

Gardasil® 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:⁶

- Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types
- Genital warts (*Condyloma acuminata*) caused by specific HPV types

Please refer to the Summary of Product Characteristics for further information prior to making any prescribing decisions.⁶

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (Tel: 0208 154 8000). By clicking the above link, you will leave the MSD website and be taken to the MHRA website.

References: 1. UK Health Security Agency. Human Papillomavirus (HPV): the green book, chapter 18a. June 2023. Available at: <https://www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a>. Last accessed: November 2024. 2. National Cancer Institute. HPV and Cancer. April 2023. Available at: <https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer>. Last accessed: November 2024. 3. Cheeson HW, et al. Sex Transm Dis. 2014;4(11):660-4. 4. Okunade KS. J Obstet Gynaecol. 2020;40:602-8. 5. The Catalan Institute of Oncology and the International Agency for Research on Cancer Information Centre on HPV and Cancer. United Kingdom Human Papillomavirus and Related Cancers, Fact Sheet 2023. March 2023. Available at: https://hpvcentre.net/statistics/reports/GBR_FS.pdf. Last accessed: November 2024. 6. Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)). Summary of Product Characteristics (SPC) for UK. Available at: <https://www.emcpi.com/pi/32240>. Last accessed: January 2025.

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.
Registered in England No. 233687
© Merck Sharp & Dohme (UK) Limited 2025. All rights reserved.
GB-GSL-00755 | January 2025